ELANE and myeloid sarcoma: Blood phenotyping has described activated neutrophils in MS with: (1) increased surface expression of toll like receptor 2 and N-Formylmethionyl-leucyl-phenylalanine receptor [24,60]; (2) higher CD11b/CD18, CD10, and CD13 expression mainly in the course of disease exacerbation compared with remission [61]; (3) enhanced neutrophil protease activity [62]; and (4) neutrophil elastase (medullasin) activity [63].